Welcome to Medications.com

Nicomide News

Dusa Pharma Q4 Net Loss Narrows - RTT News

The company noted that the Non-PDT revenues were primarily driven by the sales of Nicomide which were adversely impacted by the residual levels of the ...

http://www.rttnews.com/sp/breakin... | Posted: Tue Mar 04 08:18:00 -0500 2008

DUSA Pharmaceuticals Reports Fourth Quarter and Full Year 2007 ... - CNNMoney.com

Non-PDT revenues were primarily driven by the sales of Nicomide® which were adversely impacted by the residual levels of the River's Edge product remaining ...

http://money.cnn.com/news/newsfee... | Posted: Tue Mar 04 06:37:03 -0500 2008

Dusa Pharma Q4 Net Loss Narrows - RTT News

The company noted that the Non-PDT revenues were primarily driven by the sales of Nicomide which were adversely impacted by the residual levels of the ...

Posted: Tue Mar 04 08:18:00 -0500 2008

DUSA Pharmaceuticals Reports Fourth Quarter and Full Year 2007 ... - Trading Markets (press release)

Non-PDT revenues were primarily driven by the sales of Nicomide(R) which were adversely impacted by the residual levels of the River's Edge product ...

Posted: Tue Mar 04 06:35:47 -0500 2008

DUSA Pharmaceuticals Reports Fourth Quarter and Full Year 2007 ... - CNNMoney.com

Non-PDT revenues were primarily driven by the sales of Nicomide® which were adversely impacted by the residual levels of the River's Edge product remaining ...

Posted: Tue Mar 04 06:37:03 -0500 2008

DUSA Pharmaceuticals Reports Fourth Quarter and Full Year 2007 ... - Trading Markets (press release)

Non-PDT revenues were primarily driven by the sales of Nicomide(R) which were adversely impacted by the residual levels of the River's Edge product ...

http://www.tradingmarkets.com/.si... | Posted: Tue Mar 04 06:35:47 -0500 2008

DUSA Pharmaceuticals Reports Fourth Quarter and Full Year 2007 ... - CNNMoney.com

Non-PDT revenues were primarily driven by the sales of Nicomide® which were adversely impacted by the residual levels of the River's Edge product remaining ...

Posted: Tue Mar 04 06:37:03 -0500 2008

Dusa Pharma Q4 Net Loss Narrows - RTT News

The company noted that the Non-PDT revenues were primarily driven by the sales of Nicomide which were adversely impacted by the residual levels of the ...

Posted: Tue Mar 04 08:18:00 -0500 2008

DUSA Pharmaceuticals Reports Fourth Quarter and Full Year 2007 ... - CNNMoney.com

Non-PDT revenues were primarily driven by the sales of Nicomide® which were adversely impacted by the residual levels of the River's Edge product remaining ...

Posted: Tue Mar 04 06:37:03 -0500 2008

DUSA Pharmaceuticals, Inc. to Host Fourth Quarter and Full Year ... - PR-USA.net (press release)

DUSA's other dermatology products include ClindaReach TM and Nicomide ® . DUSA is also researching additional indications for internal uses of Levulan PDT. ...

http://www.pr-usa.net/index.php?o... | Posted: Mon Mar 03 01:04:02 -0500 2008




© 2002-2007, Skylabs Inc.  |  About Us  |  Disclaimer/Terms of Use  |  Advertise  |  Contact Us  |  Site Map  |  Developed by: W3matter.com | Sleep Apnea